Modulation of microRNAs by aspirin in cardiovascular disease.

Aspirin is among the most widely prescribed drugs in cardiovascular and cerebrovascular diseases for both primary and secondary prevention. The major mechanisms underlying its benefits are the inhibitory effects on platelet activation and prostanoid biosynthesis induced by COX-1 and COX-2 inactivation. MicroRNAs (miRNAs) are newly proposed mediators of the effects of aspirin. In this review, we summarize the evidence on the links between miRNAs and aspirin use in relation to cardiovascular diseases. In addition, we discuss the studies suggesting a possible role for miRNAs as biomarkers of aspirin resistance, a condition during which atherothrombotic events occur despite aspirin use, and which affects a considerable proportion of patients with cardiovascular disease.

• Publication year

  2020

• Venue

  Trends in cardiovascular medicine

• Publication date

  2020-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.tcm.2019.08.005PMID 31444100
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Nanoparticles Targeting STATs in Cancer Therapy

  2019cited by this paper
• Identification of aspirin resistance using a PDW-miR92a-score: Validation in an intermittent claudication cohort.

  2019cited by this paper
• Faculty Opinions recommendation of Effect of aspirin on cardiovascular events and bleeding in the healthy elderly.

  2019cited by this paper
• Mechanisms of statin‐induced new‐onset diabetes

  2019cited by this paper
• Comparison of the Neuroprotective Effects of Aspirin, Atorvastatin, Captopril and Metformin in Diabetes Mellitus

  2019cited by this paper
• 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

  2019cited by this paper
• MicroRNAs: Potential candidates for diagnosis and treatment of colorectal cancer

  2018cited by this paper
• Plasma miR-142 predicts major adverse cardiovascular events as an intermediate biomarker of dual antiplatelet therapy

  2018cited by this paper
• MicroRNA: Relevance to stroke diagnosis, prognosis, and therapy

  2018cited by this paper
• Comparison of the release of microRNAs and extracellular vesicles from platelets in response to different agonists

  2018cited by this paper
• Aspirin Resistance and Stroke

  2018cited by this paper
• Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus

  2018cited by this paper
• What Do the Guidelines Really Say About Aspirin?

  2018cited by this paper
• MicroRNAs: Novel Molecular Targets and Response Modulators of Statin Therapy.

  2018cited by this paper
• Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly

  2018influential reference
• Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.

  2018cited by this paper
• Platelet miRNA-26b down-regulates multidrug resistance protein 4 in patients on chronic aspirin treatment

  2018cited by this paper
• Inhibition of profibrotic microRNA-21 affects platelets and their releasate

  2018cited by this paper
• Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention

  2017cited by this paper
• Curcumin as a MicroRNA Regulator in Cancer: A Review.

  2016cited by this paper
• Circulating microRNA-192 as a diagnostic biomarker in human chronic lymphocytic leukemia

  2016cited by this paper
• New molecular insights into modulation of platelet reactivity in aspirin-treated patients using a network-based approach

  2016cited by this paper
• MicroRNAs in Cardiovascular Disease.

  2016cited by this paper
• Effects of Aspirin on Endothelial Function and Hypertension

  2016cited by this paper
• Association of MicroRNAs and YRNAs With Platelet Function.

  2016cited by this paper
• A brief review on the mechanisms of aspirin resistance.

  2016cited by this paper
• miR-145 mediated the role of aspirin in resisting VSMCs proliferation and anti-inflammation through CD40

  2016cited by this paper
• The role of MicroRNAs in human cancer

  2016cited by this paper
• MicroRNAs as potential diagnostic and prognostic biomarkers in melanoma.

  2016cited by this paper
• MicroRNA-34a and its target genes: Key factors in cancer multidrug resistance.

  2016cited by this paper
• MicroRNAs in Platelet Physiology and Function

  2016cited by this paper
• Aspirin resistance may be identified by miR-92a in plasma combined with platelet distribution width.

  2016cited by this paper
• Low miR-19b-1-5p expression in isolated platelets after aspirin use is related to aspirin insensitivity.

  2016cited by this paper
• Aspirin in secondary prevention of recurrent venous thromboembolism

  2015cited by this paper
• New insights into the mechanisms of action of aspirin and its use in the prevention and treatment of arterial and venous thromboembolism

  2015cited by this paper
• The Emerging Role of miR-223 in Platelet Reactivity: Implications in Antiplatelet Therapy

  2015cited by this paper
• Association of plasma miR-223 and platelet reactivity in patients with coronary artery disease on dual antiplatelet therapy: A preliminary report

  2015cited by this paper
• MicroRNAs in platelet function and cardiovascular disease

  2015cited by this paper
• MicroRNAs in cardiovascular disease: an introduction for clinicians

  2015cited by this paper
• Detection of platelet microRNA expression in patients with diabetes mellitus with or without ischemic stroke.

  2014cited by this paper
• Aspirin in the primary prevention of cardiovascular disease: current knowledge and future research needs.

  2014cited by this paper
• Decreased circulating microRNA-223 level predicts high on-treatment platelet reactivity in patients with troponin-negative non-ST elevation acute coronary syndrome

  2014cited by this paper
• Aspirin Decreases Systemic Exposure to Clopidogrel Through Modulation of P‐Glycoprotein But Does Not Alter Its Antithrombotic Activity

  2014influential reference
• Should Aspirin Be Used for the Primary Prevention of Cardiovascular Disease in the General Population?

  2014cited by this paper
• Platelets, endothelium, and circulating microRNA-126 as a prognostic biomarker in cardiovascular diseases: per aspirin ad astra.

  2013cited by this paper
• Decreased platelet miR-223 expression is associated with high on-clopidogrel platelet reactivity.

  2013cited by this paper
• Aspirin treatment hampers the use of plasma microRNA-126 as a biomarker for the progression of vascular disease.

  2013cited by this paper
• Circulating MicroRNAs as Novel Biomarkers for Platelet Activation

  2013influential reference
• Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs.

  2012cited by this paper
• MicroRNA and cancer

  2012cited by this paper
• Prospective study on circulating MicroRNAs and risk of myocardial infarction.

  2012cited by this paper
• Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy.

  2011cited by this paper
• Atherosclerosis: current pathogenesis and therapeutic options

  2011cited by this paper
• MicroRNAs in resolution of acute inflammation: identification of novel resolvin Dl‐miRNA circuits

  2011cited by this paper
• Thromboxane and the thromboxane receptor in cardiovascular disease

  2010cited by this paper
• Pathophysiology of Cyclooxygenases in Cardiovascular Homeostasis

  2010cited by this paper
• Lovastatin Decreases Acute Mucosal Inflammation Via 15-epi-Lipoxin A4

  2010cited by this paper
• Platelet alpha-granules: basic biology and clinical correlates.

  2009cited by this paper
• Inhibition of platelets and tumor cell adhesion by the disintegrin domain of human ADAM9 to collagen I under dynamic flow conditions.

  2009cited by this paper
• Effects of Low-Dose Aspirin on Acute Inflammatory Responses in Humans1

  2009cited by this paper
• Complex Regulation and Function of the Inflammatory Smooth Muscle Cell Phenotype in Atherosclerosis

  2009cited by this paper
• Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators

  2008cited by this paper
• Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells.

  2008cited by this paper
• Role of smooth muscle cells in the initiation and early progression of atherosclerosis.

  2008cited by this paper
• Laboratory detection of 'aspirin resistance': what test should we use (if any)?

  2007cited by this paper
• Aspirin resistance.

  2006cited by this paper
• Aspirin resistance

  2004cited by this paper
• Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial.

  2004cited by this paper
• Modulation of COX-2 Expression by Statins in Human Aortic Smooth Muscle Cells

  2001cited by this paper
• Lipoxin formation during human neutrophil-platelet interactions. Evidence for the transformation of leukotriene A4 by platelet 12-lipoxygenase in vitro.

  1990cited by this paper
• Clinical Pharmacology: Advances and Applications Dovepress Pharmacokinetics and Pharmacodynamics of Acetylsalicylic Acid after Intravenous and Oral Administration to Healthy Volunteers

  year unknowncited by this paper

• Longitudinal trajectory of circulating microRNA-210-3p and its association with low-dose aspirin use in gestational hypertension and preeclampsia: a pilot study.

  2026cites this paper
• MiR-21, miR-126 and miR-181b expression in Thromboangiitis obliterans.

  2025cites this paper
• An Insight Into The Evaluation of The Interaction of Escitalopram And Aspirin With Dispersion-corrected And Dispersion-free Functionals: DFT And QTAIM Analyses

  2025cites this paper
• Identification of miRNA biomarkers for essential hypertension in small samples based on MPGAM

  2025cites this paper
• Circulating microRNA signatures as potential biomarkers differentiating diabetic, prediabetic, and healthy individuals

  2025cites this paper
• Pharmacological, molecular and genetic mechanisms of acetylsalcilic acid in the secondary prevention of cardiovascular disease

  2024cites this paper
• The pharmaco-epigenetics of hypertension: a focus on microRNA

  2024influential citation
• Upregulation of miR-20b-5p inhibits trophoblast invasion by blocking autophagy in recurrent miscarriage.

  2023cites this paper
• Hybrids of carbonic anhydrase and cyclooxygenase inhibitors attenuate cardiac hypoxic inflammatory injuries.

  2023cites this paper
• Cardiovascular complications of diabetes: role of non-coding RNAs in the crosstalk between immune and cardiovascular systems

  2023influential citation
• Cardiac microRNAs: diagnostic and therapeutic potential

  2023cites this paper
• DENSITY FUNCTIONAL THEORY INVESTIGATION ON DRUG-DRUG INTERACTIONS: ESCITALOPRAM AND SALICYLIC ACID

  2022cites this paper
• Evaluation Of Platelet Aggregation Activity Depending on The Duration of Antiplatelet Administration in Patients with Coronary Heart Disease

  2022cites this paper
• A comparative study of effect of Cymbopogon citrates aqueous extract and rosuvastatin on experimentally induced hyperlipidemia in local rabbits

  2022cites this paper
• Therapeutic Effect of Bicyclol Coupled with Aspirin Nanopreparation on Liver Function Damage Caused by Epstein-Barr Virus Infection in Children

  2022cites this paper
• A guide to molecular and functional investigations of platelets to bridge basic and clinical sciences

  2022cites this paper
• Long noncoding RNA H19 suppresses cardiac hypertrophy through the MicroRNA-145-3p/SMAD4 axis

  2022cites this paper
• Noncoding RNA Roles in Pharmacogenomic Responses to Aspirin: New Molecular Mechanisms for an Old Drug

  2021cites this paper
• Epigenetics and microRNAs in cardiovascular diseases.

  2021cites this paper
• Prospective pathway signaling and prognostic values of MicroRNA-9 in ovarian cancer based on gene expression omnibus (GEO): a bioinformatics analysis

  2021cites this paper
• MicroRNA as Potential Biomarkers of Platelet Function on Antiplatelet Therapy: A Review

  2021cites this paper
• Aspirin facilitates trophoblast invasion and epithelial-mesenchymal transition by regulating the miR-200-ZEB1 axis in preeclampsia.

  2021cites this paper
• LncRNA PFAL suppresses TNF-α-induced inflammation by upregulating miR-18a in WI-38 cells

  2021cites this paper
• The Comparison of Antioxidant Effect of Aspirin, Metformin, Atorvastatin and Captopril Co-administration in the Heart and Kidney Tissues of Diabetic Rats

  2021cites this paper
• Mechanism of Improving Aspirin Resistance: Blood-Activating Herbs Combined With Aspirin in Treating Atherosclerotic Cardiovascular Diseases

  2021cites this paper
• Editorial commentary: MicroRNAs as effectors and indicators of aspirin therapeutic potential.

  2020cites this paper
• MicroRNA and hyperaggregability of platelets in women with sticky platelet syndrome and pregnancy complications.

  2020cites this paper
• The Use of Aspirin in Contemporary Primary Prevention of Atherosclerotic Cardiovascular Diseases Revisited: The Increasing Need and Call for a Personalized Therapeutic Approach

  2020cites this paper
• Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ?

  2020cites this paper
• [Primary prevention of chronic non-communicable diseases and acetylsalicylic acid: ambiguity of opinions].

  2020cites this paper
• RETRACTED ARTICLE: Long non-coding RNA NKILA weakens TNF-α-induced inflammation of MRC-5 cells by miR-21 up-regulation

  2020cites this paper
• The emergent phenomenon of aspirin resistance: insights from genetic association studies.

  2020cites this paper
• Anti-tumor activity of propofol: A focus on microRNAs.

  2020cites this paper
• MicroRNAs mediate the anti-tumor and protective effects of ginsenosides

  2020cites this paper
• Nanoparticles Targeting STATs in Cancer Therapy

  2019cites this paper